NCT06588387View on ClinicalTrials.gov

A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

210

Participants

Timeline

Start Date

November 3, 2022

Primary Completion Date

September 8, 2023

Study Completion Date

September 8, 2023

Conditions
Secondary Progressive Multiple Sclerosis
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT06588387 - A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter